drugset / Trial / NCT02964559
Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer
Phase 2
Completed
11 enrolled
Emory University
Merck Sharp & Dohme LLC · collabNational Cancer Institute (NCI) · collabNational Institutes of Health (NIH) · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial studies how well pembrolizumab works in treating patients with skin cancer that has spread from where it started to nearby tissue, lymph nodes, or other parts of the body. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread.
Timeline
- Start
- 2017-01-27
- Primary completion
- 2021-05-18
- Completion
- 2021-05-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | — | Intravenous |